Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
about
Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsIn vivo activity of ceftobiprole in murine skin infections due to Staphylococcus aureus and Pseudomonas aeruginosa.Intensive therapy with ceftobiprole medocaril of experimental foreign-body infection by methicillin-resistant Staphylococcus aureusResistance and the management of complicated skin and skin structure infections: the role of ceftobiprole.A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumoniaEmerging agents to combat complicated and resistant infections: focus on ceftobiproleIn vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.Synergistic activity of ceftobiprole and vancomycin in a rat model of infective endocarditis caused by methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects.Efficacy of ceftobiprole Medocaril against Enterococcus faecalis in a murine urinary tract infection modelAntibiotic resistance in Staphylococcus aureus and its relevance in therapy.Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria.Community-associated meticillin-resistant Staphylococcus aureusInvestigational treatments for postoperative surgical site infections.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy.Ceftobiprole: an extended-spectrum anti-methicillin-resistant Staphylococcus aureus cephalosporin.Ceftobiprole: first cephalosporin with activity against methicillin-resistant Staphylococcus aureus.Ceftobiprole: a new broad spectrum cephalosporin.Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections.β-lactams against emerging 'superbugs': progress and pitfalls.Evaluation of ceftobiprole activity against a variety of gram-negative pathogens, including Escherichia coli, Haemophilus influenzae (β-lactamase positive and β-lactamase negative), and Klebsiella pneumoniae, in a rabbit meningitis model.Comparative efficacies of tedizolid phosphate, vancomycin, and daptomycin in a rabbit model of methicillin-resistant Staphylococcus aureus endocarditis.Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.Comparative in vitro activity of ceftobiprole against staphylococci displaying normal and small-colony variant phenotypes.In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.Time-kill and synergism studies of ceftobiprole against Enterococcus faecalis, including beta-lactamase-producing and vancomycin-resistant isolatesUpdate on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections.
P2860
Q24646677-B493B511-1FB2-46F3-8D25-79C63F88984EQ33559139-F85820CE-1E47-4BD9-8946-903C41F53783Q33935282-C288944E-8450-4AFF-A9DB-4BD98F9EB7EDQ34187667-C578B7F0-0A85-4D74-9F73-36D853810D59Q34414748-FD9F16E1-129B-4EFD-8488-BA9EE03B1E5FQ35026567-07F33489-4435-46C3-958A-787BF2317C19Q35191417-257A4814-8DA0-4721-B3EA-61CCE4F01F6AQ35806369-6FD26047-8207-40B3-83D2-31155CCE7558Q35879080-028A7806-07B8-4AE8-8825-764DAF15D964Q36018587-DCB07608-B74B-4E95-BC67-080B12587354Q36283731-93E8ADE7-21A5-4586-8695-4395AB7AFD63Q36422630-9B47E146-10B7-4A1D-8E98-F830FA6D7021Q36438720-CC7D6A59-AEF9-47BF-B1B5-F5D2D7487B87Q36715742-8924420E-534E-4B56-9FA5-D019FD967873Q36718474-208AEAC4-5484-4FC6-9738-D453DC43325CQ36763997-28DE811A-2424-45EF-8E8E-59CC2D85C285Q37162872-181576FB-B4AC-4EEB-92AA-DDB795A6ABDAQ37461413-AA46B04F-D4AF-4085-BC43-361CBA13EF73Q37519733-C9B637AF-1B83-40C7-9DF5-D1BC87878452Q37593094-DC78573C-00F5-4739-BCBF-0F6A5DE71FEFQ38177344-172528DB-AFDD-4CB4-8A4E-86AE96D4508DQ40600643-C06143C5-0633-4FE8-A340-43D15A11DE86Q40675142-7D0A1428-609A-4CFB-815A-F44EC37E227EQ41814975-0B22D745-532F-4F97-93B4-00EA61487755Q41847350-BE547DA2-5625-45EA-B2D8-DF1A8F467757Q42027484-4FC76D8E-B847-4342-B7FB-CDFEC9F8F9ABQ42107999-505CA916-F27F-4035-AACC-42D3D11AAA7DQ42627381-9FE74967-3C7C-4A34-B1DF-30CFD37195CFQ42747697-26AD4EDA-3FEA-4F29-872B-BAB2E6311996Q46274310-481B645A-DEDB-4344-93F9-5DE5277B86F0
P2860
Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Evaluation of ceftobiprole in ...... mediate Staphylococcus aureus.
@en
type
label
Evaluation of ceftobiprole in ...... mediate Staphylococcus aureus.
@en
prefLabel
Evaluation of ceftobiprole in ...... mediate Staphylococcus aureus.
@en
P2860
P1476
Evaluation of ceftobiprole in ...... mediate Staphylococcus aureus.
@en
P2093
Henry F Chambers
P2860
P304
P356
10.1128/AAC.49.3.884-888.2005
P407
P577
2005-03-01T00:00:00Z